地舒单抗在骨质疏松症和肿瘤性骨病中的临床应用及挑战综述

Review in clinical application and challenges of denosumab in osteoporosis and neoplastic bone disease

地舒单抗(Dmab)作为一种核因子κB受体活化因子配体(RANKL)抑制剂,具有较好的疗效和安全性。Dmab已被批准用于治疗骨质疏松症(OP)、骨巨细胞瘤(GCTB)、多发性骨髓瘤(MM)以及实体瘤骨转移患者。但在临床实际应用中,Dmab面临着用药疗程、停药序贯、局部复发等问题。本文综述了Dmab在OP和肿瘤性骨病中的临床应用以及挑战,旨在为临床治疗提供依据。

Denosumab(Dmab)is a receptor activator of NF-kappaB ligand(RANKL)inhibitor with better efficacy and safety.Dmab has been approved to treat patients with osteoporosis(OP),giant cell tumor of bone(GCTB),multiple myeloma(MM)and bone metastases from solid tumors.However,in clinical practice,Dmab is faced with problems such as drug duration,drug withdrawal sequence and local recurrence.This article reviewed the clinical application and challenges of Dmab in OP and neoplastic bone disease,aiming to provide evidence for clinical treatment.